Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapeutics symbols : Vera save search
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
Published: 2024-04-02 (Crawled : 12:00) - globenewswire.com
VERA | $39.51 -1.25% -1.27% 860K
|
Professional, Scientific, and T...
|
| O: -3.66%
H: 0.0%
C: 0.0%
congress association renal therapeutics
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-03-20 (Crawled : 12:00) - biospace.com/
VERA | $39.51 -1.25% -1.27% 860K
|
Professional, Scientific, and T...
|
| O: -1.77%
H: 8.63%
C: 6.28%
business year update therapeutics financial results
Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
Published: 2024-02-28 (Crawled : 21:00) - globenewswire.com
VERA | $39.51 -1.25% -1.27% 860K
|
Professional, Scientific, and T...
|
| O: 6.46%
H: 0.0%
C: -3.74%
conference health care therapeutics
Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Published: 2024-02-02 (Crawled : 13:00) - globenewswire.com
VERA | $39.51 -1.25% -1.27% 860K
|
Professional, Scientific, and T...
|
| O: 2.24%
H: 1.98%
C: 0.77%
conference therapeutics
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
Published: 2024-02-01 (Crawled : 21:00) - globenewswire.com
VERA | $39.51 -1.25% -1.27% 860K
|
Professional, Scientific, and T...
|
| O: 2.24%
H: 1.98%
C: 0.77%
offering therapeutics
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
Published: 2024-01-30 (Crawled : 05:00) - globenewswire.com
VERA | $39.51 -1.25% -1.27% 860K
|
Professional, Scientific, and T...
|
| O: 3.78%
H: 4.2%
C: -1.15%
offering therapeutics
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
Published: 2024-01-29 (Crawled : 12:00) - globenewswire.com
VERA | $39.51 -1.25% -1.27% 860K
|
Professional, Scientific, and T...
|
| O: -1.09%
H: 18.63%
C: 12.7%
offering therapeutics
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
Published: 2024-01-25 (Crawled : 12:00) - globenewswire.com
VERA | $39.51 -1.25% -1.27% 860K
|
Professional, Scientific, and T...
|
| O: 30.79%
H: 19.79%
C: 13.7%
nephropathy origin positive trial therapeutics
Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer
Published: 2024-01-08 (Crawled : 13:00) - globenewswire.com
VERA | $39.51 -1.25% -1.27% 860K
|
Professional, Scientific, and T...
|
| O: 0.58%
H: 17.29%
C: 16.07%
DVAX | $11.35 -0.7% -0.7% 2.2M
|
Health Technology
|
| O: -0.34%
H: 0.14%
C: -4.9%
medical therapeutics
Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2023-12-27 (Crawled : 13:00) - globenewswire.com
VERA | $39.51 -1.25% -1.27% 860K
|
Professional, Scientific, and T...
|
| O: 0.88%
H: 4.84%
C: -1.18%
conference therapeutics
Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results
Published: 2023-11-09 (Crawled : 13:00) - globenewswire.com
VERA | $39.51 -1.25% -1.27% 860K
|
Professional, Scientific, and T...
|
| O: -2.08%
H: 6.56%
C: 2.04%
business update therapeutics financial results
Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023
Published: 2023-11-04 (Crawled : 16:20) - globenewswire.com
VERA | $39.51 -1.25% -1.27% 860K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
kidney origin positive week therapeutics study
Vera Therapeutics Scheduled to Present at November Investor Conferences
Published: 2023-10-30 (Crawled : 12:00) - globenewswire.com
VERA | $39.51 -1.25% -1.27% 860K
|
Professional, Scientific, and T...
|
| O: 0.5%
H: 9.77%
C: 7.78%
therapeutics
Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting
Published: 2023-10-13 (Crawled : 14:30) - globenewswire.com
VERA | $39.51 -1.25% -1.27% 860K
|
Professional, Scientific, and T...
|
| O: 2.88%
H: 0.61%
C: -0.56%
kidney meeting week therapeutics
Vera Therapeutics Scheduled to Present at September Investor Conferences
Published: 2023-08-31 (Crawled : 12:00) - globenewswire.com
VERA | $39.51 -1.25% -1.27% 860K
|
Professional, Scientific, and T...
|
| O: -0.05%
H: 0.75%
C: -5.65%
therapeutics
Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results
Published: 2023-08-10 (Crawled : 12:20) - globenewswire.com
VERA | $39.51 -1.25% -1.27% 860K
|
Professional, Scientific, and T...
|
| O: 1.14%
H: 7.49%
C: 5.03%
business update therapeutics financial results
Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress
Published: 2023-06-17 (Crawled : 16:20) - globenewswire.com
VERA | $39.51 -1.25% -1.27% 860K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
association renal presentation origin positive week trial therapeutics results igan
Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN
Published: 2023-06-15 (Crawled : 21:00) - globenewswire.com
VERA | $39.51 -1.25% -1.27% 860K
|
Professional, Scientific, and T...
|
| O: 2.36%
H: 7.22%
C: -1.15%
presentation origin week trial therapeutics igan
Vera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
Published: 2023-06-08 (Crawled : 12:00) - globenewswire.com
VERA | $39.51 -1.25% -1.27% 860K
|
Professional, Scientific, and T...
|
| O: 0.11%
H: 3.22%
C: -3.44%
conference global therapeutics
Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (IgAN)
Published: 2023-06-07 (Crawled : 12:00) - globenewswire.com
VERA | $39.51 -1.25% -1.27% 860K
|
Professional, Scientific, and T...
|
| O: 0.44%
H: 4.82%
C: -1.32%
nephropathy treatment trial therapeutics igan
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.